Telix announces astatine-211 production partnership with Ekalia
Telix Pharmaceuticals (NASDAQ:TLX) announced a collaboration with Ekalia to develop U.S. production of astatine-211, starting with one cyclotron installation near Philadelphia.
Telix Pharmaceuticals (NASDAQ:TLX) announced a collaboration with Ekalia to develop U.S. production of astatine-211, starting with one cyclotron installation near Philadelphia.
Oculis (NASDAQ:OCS) completed randomization of 176 patients in its PREDICT-1 registrational trial of Licaminlimab, advancing its development program for dry eye disease.
The US Department of Justice announced 28 arrests following an international operation targeting scam networks across West Africa
Elbit Systems (NASDAQ:ESLT) secured an approximately US$235 million contract to supply rocket artillery systems, including EXTRA-MR rockets and PULS launchers, to a European customer.
Evaxion (NASDAQ:EVAX) reported sustained clinical responses after three years in its phase 2 melanoma vaccine trial, with no tumor progression among six patients followed.
Solana (SOL) has gone more than two years without a major mainnet outage, according to Fidelity’s Center for Applied Technology (FCAT).
Critical Minerals Group (ASX:CMG) has secured firm commitments and launched a purchase plan to raise up to $2.1 million.
Werner Enterprises (NASDAQ:WERN) expects third-quarter 2026 revenue of $946 million to $951 million, with preliminary GAAP diluted earnings of $0.10 to $0.11 per share.
South Korea plans to meet representatives from five major cryptocurrency exchanges on 20 October to discuss the planned tax, according to Yonhap News Agency.
Deutsche Bank AG (XETRA:DBK) plans to launch digital asset custody for institutional and corporate clients in Europe this year, subject to regulatory approval.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy